Clinical trials focus on new treatments for Crohn's Disease, dangerous bacterium

By Katie Pence

Several clinical trials at the University of Cincinnati (UC) are focused on potential treatments for two serious gastroenterological illnesses—Crohn’s disease and Clostridium difficile, or C. difficile.

Bruce Yacyshyn, MD, professor of medicine in the division of digestive diseases and principal investigator for the Cincinnati sites on both multicenter, international trials, says researchers are working with the pharmaceutical companies Janssen and Merck to find new therapies for a potentially life-altering autoimmune disease and for a condition, once only common in the autoimmune-compromised hospital population, that is now becoming an epidemic within the general population.

Yacyshyn says the first study—called UNITI-1—will examine how a Food and Drug Administration (FDA)-approved drug used for psoriasis may help in treating patients with Crohn’s disease who experience treatment failure with the other drugs commonly prescribed.

Crohn’s disease is an inflammatory bowel disease that occurs when the immune system attacks the gastrointestinal tract. Crohn’s can affect any part of the tract and inflame all layers of the intestinal wall; it most typically begins in younger years, with an average age of trouble occurring at 36.

Besides experiencing abdominal pain, bloody stools, diarrhea and other serious problems, such as growth failure because of a lack of nutrients, individuals with Crohn’s have an increased risk of colorectal cancer.

"There are currently three FDA-approved monoclonal biologic treatments for Crohn’s disease,” Yacyshyn says, explaining that these treatments are helpful because they target a pathway which activates the immune response in the body and produces the proteins that attack the gastrointestinal tract.”

"This clinical trial will focus on a therapy that will target a different pathway, giving hope to patients who have not experienced success with one of the other treatments or whose treatments begin to lose effect,” he adds.

The second clinical trial is looking at a single injection to see if this treatment could clear initial or recurrent onset of C. difficile.

C. difficile is a bacterium that can be naturally found inside the digestive tract, but if an overgrowth occurs, it can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Illness from C. difficile was once more common in older adults who were hospitalized or among people in long-term care facilities, and typically occurred after use of antibiotic medications.

"In recent years, C. diff infections have become more frequent, more severe and more difficult to treat,” says Yacyshyn, adding that treatment is expensive, ranging anywhere from $4,000 to $9,000. "Tens of thousands of people in the U.S. get sick from C. diff each year, and a rise in cases is being seen in the community—in healthy people who aren't hospitalized or taking antibiotics.”

In this Phase III trial, researchers will be giving individuals who currently test positive for C. difficile one of two antibodies which recognize the toxins produced by the bacteria.

"The infusion will be given with concurrent, standard-of-care antibiotic therapy. Following this one-time infusion, follow-up will occur over three months with a possible follow-up extension to nine months,” says Yacyshyn, adding that this is for patients 18 years or older. "There is currently no optimal treatment for all C. difficile-positive patients, and the antibiotics usually prescribed for it are not effective in all cases.  

"Addition of this treatment alongside current standard-of-care treatment may cut down on recurrence and help clear both toxin and bacteria after initial infection.

"While different, both of these conditions affect a large number of the population and could cause major complications if not treated properly,” he adds. "The hope is that these help in uncovering additional or more beneficial treatments for Crohn’s disease and C. difficile.”

More information: Yacyshyn receives research support from Merck but cites no other conflict of interest.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Sierra Leone streets deserted as shutdown begins

48 minutes ago

Sierra Leone's normally chaotic capital was transformed on Friday as residents were confined to their homes for the start of a three-day lockdown aimed at halting the deadly Ebola epidemic.

Sierra Leone launches controversial Ebola shutdown

2 hours ago

Sierra Leone on Friday launched a controversial three-day shutdown to contain the deadly spread of the Ebola virus, as the UN Security Council declared the deadly outbreak a threat to world peace.

Cooling of dialysis fluids protects against brain damage

15 hours ago

While dialysis can cause blood pressure changes that damage the brain, cooling dialysis fluids can protect against such effects. The findings come from a study appearing in an upcoming issue of the Journal of the American So ...

Two Ebola vaccines to be tested in Switzerland

15 hours ago

Clinical trials of two experimental vaccines against the deadly Ebola virus are due to begin soon in Switzerland, the country's Tropical and Public Health Institute said on Thursday.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Laurettas
not rated yet Mar 21, 2012
I believe the FDA has announced that PPI use can increase the chances of getting C diff. Since there are millions of people on PPI's, might that not be a contributing cause to C diff's increased cases?
vcb
not rated yet Mar 21, 2012
I am a Crohn's patient, when will this study start?
DDBear
not rated yet Mar 21, 2012
Why is Crohn's becoming more common in the general population? Probably because food makers are increasingly putting unhealthy ingredients such as corn syrup in just about every product and it is hard for people to avoid. The billions the government spends on taxpayer subsidies for corn (to produce corn syrup) is one of the biggest scandals that so far is receiving little attention.